HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 07, July 2021 – Ageing Better – Breakthroughs and Innovations for a Greying World       » A Plant-Based Remedy for Big, Broken Hearts       » Fuelling the Future with Multi-Element Alloys and Green Hydrogen       » RADICA: A Radical, Rapid Method for Accurate Detection of Viruses       » Untangling the Twists of Alzheimer’s Plaques       » Turning Aquaculture Trash to Treasure for Tissue Repair      
Vol 25, No. 06, June 2021   |   Issue PDF view/purchase
INSIDE INDUSTRY
BioNTech to Establish Regional Headquarters for Southeast Asia and First mRNA Manufacturing Facility in Singapore
Planned state-of-the-art manufacturing site by BioNTech will support global supply of mRNA-based vaccines and therapeutics and provide a rapid response capability for Southeast Asia against potential future pandemic threats.

BioNTech SE announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for Southeast Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manufacturing facility in Singapore with support from the Singapore Economic Development Board. The new facility will provide regional and global supply capacity of BioNTech’s growing pipeline of mRNA-based product candidates, as well as a rapid response production capability for Southeast Asia to address potential pandemic threats.

In line with BioNTech’s mission to develop next-generation immunotherapies to improve the health of individuals worldwide, the new mRNA manufacturing facility will leverage cutting-edge manufacturing and digital infrastructure. It will be equipped to produce a range of novel mRNA vaccines and therapeutics for infectious diseases and cancer. The envisioned site will bring highly automated and end-to-end mRNA production capabilities across drug substance, drug product and fill-and-finish, with an estimated annual capacity of several hundred of million doses of mRNA-based vaccines depending on the specific vaccine.

BioNTech plans to open its Singapore office and initiate construction of the manufacturing facility in 2021, subject to planning approval. The Company anticipates that the site could be operational as early as 2023 and will create up to 80 jobs in Singapore.

“Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities. With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.

“Singapore provides an excellent business climate, growing biotechnology industry and rich talent base. We would like to thank Singapore’s Economic Development Board who has been very supportive throughout our planning process, and we look forward to contributing our technology and expertise to the development of the biotechnology industry in Singapore and this region.”

“We strongly welcome BioNTech’s plan to establish its mRNA manufacturing facility and regional headquarters in Singapore. The investment will enable Singapore to develop capabilities in an important new therapeutic modality as part of the strategy to grow our biopharmaceutical industry,” said Dr. Beh Swan Gin, Chairman, EDB. “In particular, BioNTech’s mRNA manufacturing facility will contribute significantly to the region’s ability to address future pandemic threats.”

Following the establishment of its U.S. Headquarters in Cambridge, MA in 2020, the establishment of BioNTech’s Southeast Asia Headquarters represents a key milestone in the Company’s international expansion.

NEWS CRUNCH  
news Singapore Health & Biomedical Congress 2021 is Set to Brave the New Frontiers as We Revolutionise and Transform Healthcare
news Anti-Pandemic Forum to be Hosted by Top-Notch American and Chinese Scientists
news Commemorating World Health Day with Viatris
news Entire industrial chain resources of advanced medical equipment are lining up at Medtec China 2021
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy